All Outputs (4)

Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles (2021)
Journal Article
Baghdadi, N. E., Burke, B. P., Alresheedi, T., Nigam, S., Saeed, A., Almutairi, F., Domarkas, J., Khan, A., & Archibald, S. J. (2021). Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles. Dalton Transactions : an international journal of inorganic chemistry, 50(5), 1599-1603. https://doi.org/10.1039/d0dt02626c

The CXCR4 chemokine receptor is an important biomolecular target in cancer diagnostics and therapeutics. In a new multivalent approach, iron oxide nanoparticles were conjugated with multiple binding units of a low affinity azamacrocylic CXCR4 antagon... Read More about Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles.

CXCR4 chemokine receptor antagonists : new metallodrugs (2009)
Thesis
Khan, A. CXCR4 chemokine receptor antagonists : new metallodrugs. (Thesis). University of Hull. https://hull-repository.worktribe.com/output/4216132

Chemokine receptors are a target of growing interest for new therapeutic drugs, as their role in multiple disease states has been demonstrated. The CXCR4/ CXCL12 pairing has been implicated in HIV and cancer, as well as chronic inflammatory diseases,... Read More about CXCR4 chemokine receptor antagonists : new metallodrugs.

CXCR4 antagonists: a new generation of configurationally restricted bis-azamacrocyclic compounds (2009)
Journal Article
Khan, A., Nicholson, G., McRobbie, G., Greenman, J., Pannecouque, C., Daelemans, D., Schols, D., De CLercq, E., Hubin, T. J., & Archibald, S. J. (2009). CXCR4 antagonists: a new generation of configurationally restricted bis-azamacrocyclic compounds. Antiviral research, 82(2), A59-A60. https://doi.org/10.1016/j.antiviral.2009.02.141

AMD3100 is a bis-azamacrocyclic compound that has been demonstrated to be a highly effective antagonist of the CXCR4 chemokine receptor. The two azamacrocyclic rings have been shown to interact with aspartate residues on the receptor via hydrogen bon... Read More about CXCR4 antagonists: a new generation of configurationally restricted bis-azamacrocyclic compounds.

Binding Optimization through Coordination Chemistry: CXCR4 Chemokine Receptor Antagonists from Ultrarigid Metal Complexes (2009)
Journal Article
Khan, A., Nicholson, G., McRobbie, G., Pannecouque, C., De Clercq, E., Ullom, R., Maples, D. L., Maples, R. D., Silversides, J. D., Hubin, T. J., Archibald, S. J., Madden, L., & Greenman, J. (2009). Binding Optimization through Coordination Chemistry: CXCR4 Chemokine Receptor Antagonists from Ultrarigid Metal Complexes. Journal of the American Chemical Society, 131(10), 3416-3417. https://doi.org/10.1021/ja807921k

A new copper(II) containing bis-macrocyclic CXCR4 chemokine receptor antagonist is shown to have improved binding properties to the receptor protein in comparison to the drug AMD3100 (Plerixafor, Mozobil). The interaction of the metallodrug has been... Read More about Binding Optimization through Coordination Chemistry: CXCR4 Chemokine Receptor Antagonists from Ultrarigid Metal Complexes.